Does UnitedHealthcare Cover Weight Loss Treatment In Delaware? A 2026 Guide

Last updated: July 22, 2026

If you have UnitedHealthcare (UHC) insurance in Delaware and are seeking treatment for weight loss, understanding your coverage may help you access medications with fewer surprises. UHC plans in Delaware may cover weight loss treatment, including GLP-1 medications, appetite suppressants, and lifestyle counseling, but coverage is often an optional benefit that varies by plan. This guide explains how UHC weight loss coverage works in Delaware in 2026, what OptumRx formulary tiers apply to common weight loss medications, when prior authorization may be required, and how to appeal a denial.

Key Facts at a Glance

Insurer: UnitedHealthcare (UHC) | PBM: OptumRx

State: Delaware | Parity Law: Del. Code Ann. tit. 18, § 3343 does NOT govern weight loss (MH/SUD parity only)

EPCS: GLP-1s (semaglutide, tirzepatide, liraglutide), Contrave, orlistat are non-scheduled. EPCS inapplicable. Phentermine and Qsymia are Schedule IV = EPCS REQUIRED. Delaware also requires ALL prescriptions to be issued electronically.

Contacts: UHC 1-866-774-2884 | OptumRx 1-800-788-4863 | DE Insurance Commissioner 1-302-674-7300

Klarity Health connects patients in Delaware with licensed providers who can evaluate weight loss needs, prescribe GLP-1 medications and appetite suppressants when clinically appropriate, and help navigate prior authorization with your insurer.

→ See if you may qualify for weight loss treatment through Klarity Health

Does UnitedHealthcare Cover Weight Loss Treatment in Delaware?

UHC plans sold in Delaware may cover weight loss treatment, but weight loss medications are typically an optional benefit. Not all UHC plans include coverage for weight loss or appetite suppression medications. Coverage depends on whether your employer or plan has elected to include this benefit.

For plans that do cover weight loss treatment, covered services may include:

• GLP-1 receptor agonist medications (Zepbound, Wegovy) through the OptumRx pharmacy benefit
• Appetite suppressants (phentermine, Qsymia) through the OptumRx pharmacy benefit
• Non-stimulant weight loss medications (Contrave, orlistat) through the OptumRx pharmacy benefit
• Nutritional counseling and lifestyle modification programs

Delaware’s mental health parity law (Del. Code Ann. tit. 18, § 3343) does NOT apply to weight loss treatment. That statute covers mental health and substance use disorder benefits only. There is no Delaware-specific weight loss parity law. Coverage for weight loss medications is governed by your plan’s benefit design and the Affordable Care Act’s Essential Health Benefits framework, which may or may not include obesity treatment depending on your plan type.

Coverage details, copays, deductibles, and prior authorization requirements depend on your specific UHC plan. Always verify benefits directly with UHC at 1-866-774-2884 before scheduling care.

OptumRx Weight Loss Medication Formulary (Delaware, 2026)

UHC uses OptumRx as its pharmacy benefit manager (PBM) in Delaware. For plans that have elected weight loss medication coverage, OptumRx maintains a prior authorization program for weight loss and appetite suppression medications. Zepbound (tirzepatide) is currently on the preferred drug list. Wegovy and Saxenda have been removed from the preferred drug list but may still be covered with prior authorization for specific indications.

Weight loss medications that may be covered under UHC plans in Delaware include:

Formulary placement and PA requirements may vary by plan year and specific UHC plan. Some UHC plans do not cover weight loss medications at all. Verify your plan’s drug list at myuhc.com or call OptumRx at 1-800-788-4863.

Prior Authorization Criteria for UHC Weight Loss Medications in Delaware

For UHC plans in Delaware that include weight loss medication coverage, OptumRx requires prior authorization for most weight loss medications. The following criteria generally apply for initial authorization:

Initial Authorization Requirements

• Indication: Treatment is being requested for appetite suppression or weight loss. Wegovy may also be requested for cardiovascular risk reduction in adults with established cardiovascular disease, or for treatment of metabolic dysfunction-associated steatohepatitis (MASH). Zepbound may also be requested for moderate to severe obstructive sleep apnea.
• Age: Patient must be ≥12 years of age (for Qsymia, Saxenda, and Wegovy injection) or >16 years of age (for all other weight loss medications)
• BMI criteria (one of the following):
  • BMI ≥30 kg/m², OR
  • BMI ≥27 kg/m² with at least one weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)
• Lifestyle counseling: Patient has been counseled to continue a reduced-calorie diet and increased physical activity
• Baseline weight: Documented baseline weight must be submitted

Initial Authorization Duration

• Phentermine, benzphetamine, diethylpropion, phendimetrazine: 3 months
• Contrave, Qsymia, Saxenda: 4 months
• Wegovy (injection or tablet): 5 months
• Zepbound, Xenical (orlistat): 6 months

Reauthorization Criteria

To continue coverage after the initial authorization period, patients must demonstrate documented weight loss:

• Qsymia: ≥3% of baseline body weight
• Saxenda: ≥4% of baseline body weight
• Wegovy, Zepbound, and all other medications: ≥5% of baseline body weight
• Continuation of lifestyle modification must be documented

Reauthorization is typically issued for 12 months for GLP-1s and non-stimulant medications, and 6 months for phentermine and similar stimulant-type appetite suppressants.

Step Therapy

UHC has removed the step therapy requirement that patients trial Wegovy or Saxenda before requesting Zepbound. However, for certain plans, patients may need to trial phentermine (with or without topiramate) before requesting prior authorization for Zepbound. Check your specific plan requirements.

Delaware EPCS Requirements for Weight Loss Medications

Delaware requires all prescriptions to be issued electronically, including non-controlled medications. This is a universal e-prescribing mandate that goes beyond controlled substances. For weight loss medications, the EPCS (Electronic Prescribing of Controlled Substances) framework applies specifically to scheduled medications:

For telehealth providers prescribing weight loss medications to Delaware patients, the EPCS distinction is important: GLP-1 medications (Zepbound, Wegovy, Saxenda) and non-stimulant medications (Contrave, orlistat) can be prescribed electronically without the enhanced DEA EPCS security requirements. However, phentermine and Qsymia, as Schedule IV controlled substances, require full EPCS-compliant electronic prescribing with two-factor authentication and identity proofing.

Weight Loss Coverage and Delaware Law

Unlike mental health conditions, weight loss treatment is not covered under Delaware’s parity law (Del. Code Ann. tit. 18, § 3343). That statute applies to mental health and substance use disorder benefits only. There is no Delaware-specific weight loss parity law requiring insurers to cover obesity treatment.

For commercial plans, the Affordable Care Act’s Essential Health Benefits framework may include some preventive obesity services, but coverage of weight loss medications is generally optional. UHC plans in Delaware that include weight loss medication coverage typically do so through the OptumRx pharmacy benefit with prior authorization requirements.

If your UHC plan does not cover weight loss medications, you may:

• Contact UHC Member Services at 1-866-774-2884 to confirm whether your plan includes the weight loss pharmacy benefit
• Ask your employer’s HR department whether weight loss medication coverage can be added to your plan
• Explore cash-pay options through providers like Klarity Health, which offers transparent pricing for weight loss consultations and prescriptions

How to Appeal a UHC Weight Loss Coverage Denial in Delaware

If UHC denies coverage for a weight loss medication, you have the right to appeal. The process generally follows these steps:

1. Internal appeal with UHC: File a formal appeal with UHC within 180 days of the denial. Include a letter of medical necessity from your prescriber, BMI documentation, comorbidity records, and evidence of prior treatment failures if applicable.
2. External review via DE DOI: If UHC upholds the denial, you may request independent external review through the Delaware Department of Insurance (1-302-674-7300). An independent reviewer will evaluate whether UHC’s denial meets clinical standards and plan terms.
3. File a complaint with DE DOI: You may also file a consumer complaint with the Delaware Insurance Commissioner’s office if you believe UHC has acted in bad faith or violated Delaware insurance regulations.
4. DOL EBSA (ERISA plans): If your coverage is through an employer-sponsored self-funded plan, contact the U.S. Department of Labor’s Employee Benefits Security Administration (EBSA) at 1-866-444-3272 for ERISA enforcement assistance.

Note: Because weight loss is not a mental health condition, the parity complaint pathway under § 3343 is not available for weight loss medication denials. Standard appeal and external review processes apply.

Get Connected with a Weight Loss Prescriber Through Klarity Health

Klarity Health works with a network of 2,000+ licensed providers across Delaware and nationwide who evaluate and treat weight loss via telehealth. Klarity providers can prescribe GLP-1 medications (Zepbound, Wegovy), appetite suppressants, and non-stimulant weight loss medications when clinically appropriate, submit prior authorization documentation to OptumRx, and support appeals when coverage is denied.

Many UHC plans may cover telehealth visits with Klarity providers. Coverage varies by plan. Verifying your benefits before your first appointment is recommended. For patients whose UHC plans do not cover weight loss medications, Klarity also offers cash-pay options with transparent pricing.

→ See if you may qualify for weight loss treatment through Klarity Health

Frequently Asked Questions

Does UHC cover Zepbound in Delaware?

UHC plans in Delaware that include weight loss medication coverage may cover Zepbound (tirzepatide) with prior authorization. Zepbound is currently on UHC’s preferred drug list. PA criteria typically require a BMI ≥30, or BMI ≥27 with a weight-related comorbidity, plus documentation of diet and exercise counseling. Initial authorization is typically for 6 months. Not all UHC plans include the weight loss pharmacy benefit. Call UHC at 1-866-774-2884 to verify your plan’s coverage.

Does UHC cover Wegovy in Delaware?

Wegovy (semaglutide) may be covered under UHC plans in Delaware that include weight loss medication coverage. Wegovy has been removed from the preferred drug list but remains available with prior authorization. Wegovy may also be covered for cardiovascular risk reduction in adults with established cardiovascular disease, and for treatment of MASH (metabolic dysfunction-associated steatohepatitis). Initial authorization is typically for 5 months.

Do I need EPCS for weight loss medications in Delaware?

For GLP-1 medications (Zepbound, Wegovy, Saxenda) and non-stimulant medications (Contrave, orlistat), no. These are non-scheduled, making EPCS inapplicable. However, Delaware requires all prescriptions to be issued electronically, so electronic prescribing is still required for these medications. For phentermine and Qsymia (Schedule IV controlled substances), full DEA EPCS requirements apply, including two-factor authentication and identity proofing.

Does UHC cover phentermine in Delaware?

Generic phentermine may be covered under UHC plans in Delaware that include weight loss medication coverage, typically at Tier 1-2. Some plans do not require prior authorization for generic phentermine. Lomaira (a branded phentermine product) requires prior authorization. Phentermine is a Schedule IV controlled substance, so EPCS is required in Delaware. Your prescriber must use an EPCS-compliant electronic prescribing system.

What BMI do I need for UHC to cover weight loss medication in Delaware?

UHC’s prior authorization criteria typically require a BMI ≥30 kg/m², or a BMI ≥27 kg/m² with at least one weight-related comorbidity such as dyslipidemia, hypertension, type 2 diabetes, or sleep apnea. Your prescriber must document your baseline BMI, baseline weight, and evidence that you have been counseled on diet and exercise. These criteria may vary by plan. Confirm specific requirements with OptumRx at 1-800-788-4863.

What can I do if UHC denies my weight loss medication claim in Delaware?

You may file an internal appeal with UHC within 180 days of the denial. If UHC upholds the denial, you may request independent external review through the Delaware Department of Insurance (1-302-674-7300). If you are on an employer-sponsored self-funded plan, you may also contact DOL EBSA at 1-866-444-3272. Because weight loss is not a mental health condition, the parity complaint pathway under § 3343 is not available. Standard appeal and external review processes apply.

Key Contacts

• UnitedHealthcare Member Services: 1-866-774-2884
• OptumRx Pharmacy Help Desk: 1-800-788-4863
• Delaware Department of Insurance: 1-302-674-7300
• DOL Employee Benefits Security Administration (ERISA): 1-866-444-3272

Disclaimer: Coverage information in this guide is based on general knowledge of UHC and OptumRx policies as of 2026 and is provided for informational purposes only. Actual coverage, formulary placement, prior authorization requirements, and out-of-pocket costs may vary by specific plan, employer group, and plan year. Weight loss medication coverage is an optional benefit and not all UHC plans include it. Always verify your benefits directly with UHC at 1-866-774-2884 or OptumRx at 1-800-788-4863 before beginning treatment. This guide does not constitute medical or legal advice.